Original article
Intrapleural bupivacaine ν saline after thoracotomy—effects on pain and lung function—a double-blind study

https://doi.org/10.1016/S0888-6296(89)92306-5Get rights and content

The effects of intrapleural (IP) bupivacaine on pain, morphine requirement, and pulmonary function were evaluated in 15 patients for 24 hours after thoracotomy. An IP catheter was placed during surgery. Patients were randomized in a double-blind fashion to receive 1.5 mg/kg of 0.5% bupivacaine IP or saline on two occasions, eight hours apart. A standard anesthetic with thiopental, oxygen, isoflurane, and nondepolarizing muscle relaxant was given. Pain was evaluated with a visual analog pain score every hour, and forced vital capacity (FVC1), forced expiratory volume one second (FEV1), peak expiratory flow (PF), and forced expiratory flow 25% to 75% (FEF) were measured 1, 2, 4, 8, and 24 hours postoperatively as well as before and 30 minutes after each IP injection. Arterial blood gases were sampled 1, 2, 8, and 24 hours postoperatively. Plasma bupivacaine concentrations were measured in 10 patients 5, 10,20,30,60, 120, and 180 minutes after IP injection. With each IP bupivacaine injection, the pain score and morphine requirement decreased. There was a significant improvement in all pulmonary function tests in the patients receiving bupivacaine, but no change in the saline controls. The analgesic effect was shortlived (two to five hours), possibly because of loss of bupivacaine in the chest drains. No differences were seen between the two groups after the effect of IP bupivacaine had worn off. Plasma bupivacaine levels had a Cmax of 0.44 to 1.50 μg/mL, with a Tmax at 5 to 30 minutes with levels well below 2 to 4 μg/mL where increasing toxicity is seen.

References (18)

There are more references available in the full text version of this article.

Cited by (56)

  • Chronic cancer pain syndromes and their treatment

    2022, Neurological Complications of Systemic Cancer and Antineoplastic Therapy
  • Respiratory Chest Pain: Diagnosis and Treatment

    2010, Medical Clinics of North America
    Citation Excerpt :

    Their use for patients with acute pleuritic chest pain is limited but may have a role in those with neuropathic pain (eg, using tricyclic antidepressants or anticonvulsants)18 and persistent pain syndromes. The use of intrapleural local anesthetic agents for postoperative (eg, thoracotomy19–28 and sympathectomy29) and posttrauma pain30,31 has been studied with varying results. One randomized trial showed decreased pain with the use of intrapleural local anesthetic in patients with spontaneous pneumothorax.32

  • Chest Tube-Delivered Bupivacaine Improves Pain and Decreases Opioid Use After Thoracoscopy

    2009, Annals of Thoracic Surgery
    Citation Excerpt :

    Thoracic surgeons and anesthesiologists have tried various regional techniques to reduce postoperative discomfort. Several prospective, randomized studies showed benefits to intrapleural anesthetic deliveries [1–3; 7–9]. However, other investigators who attempted to replicate those results found that intrapleural bupivacaine alone could not lower the pain scores to acceptable levels, that a placebo effect was at play, and that the methodologies themselves were prone to considerable variations [10–12].

  • Efficacy of methods of intercostal nerve blockade for pain relief after thoracotomy

    2005, Annals of Thoracic Surgery
    Citation Excerpt :

    Other complications have included upper extremity tingling and urinary retention [42, 43]. Average plasma bupivacaine levels have generally been approximately 1 μg/mL (0.32 to 2.29 μg/mL) [33, 39, 42, 43, 45], but there is wide individual variation among patients [35]. The amount of bupivacaine lost in the chest tubes does not seen to correlate with either the plasma levels or the degree of pain relief [36, 37].

  • Double-blind comparison of intrapleural saline and 0.25% bupivacaine for ipsilateral shoulder pain after thoracotomy in patients receiving thoracic epidural analgesia

    2005, British Journal of Anaesthesia
    Citation Excerpt :

    We considered that, to be clinically useful, intrapleural bupivacaine would need to be safe and repeatable and thus effective after modest doses (1.5 mg kg−1). Peak plasma bupivacaine concentrations in patients undergoing thoracotomy who received 1.5 mg kg−1 of intrapleural bupivacaine (40 ml of bupivacaine 0.25% for a 70 kg patient) have been shown to be 1.50 μg ml−1.17 Increasing toxicity is seen with plasma bupivacaine levels above 2–4 μg ml−1.

View all citing articles on Scopus

This article is accompanied by an editorial. Please see: Camporesi EM: Intrapleural analgesia: A new technique. J Cardiothorac Anesth 3:137–138, 1989.

Support was provided by the Anesthesia Department, University of Iowa Hospitals and Clinics CLINFO, and by Grant RR 59 from Clinical Research Centers Branch, NIH.

View full text